Abstract Lung transplantation for scleroderma-related lung disease is considered a controversial procedure due to extrapulmonary organ involvement that may threaten allograft and patient survival after transplant surgery. Despite concerns, however, several lung transplant programs do offer this option for patients with scleroderma-related lung disease. In this review, we evaluate the scleroderma-related extrapulmonary organ involvement that may result in poorer outcomes as well as the existing evidence on survival, freedom from bronchiolitis obliterans syndrome (BOS), and other important clinical outcomes after lung transplantation. Among the nine studies comprising 226 subjects included in this review, survival and freedom from BOS appear to be similar for subjects undergoing lung transplantation for scleroderma compared to nonscleroderma lung diseases. Although scleroderma is a systemic disease with several unique potential threats to allograft and patient survival, lung transplantation seems to be a reasonable intervention for this patient population.
Introduction
Scleroderma is an incurable connective tissue disease characterized by fibrosis of the skin and internal organs.
Also called systemic sclerosis, it most commonly affects the heart, lungs, proximal gastrointestinal system, and kidneys [1] . The incidence of scleroderma ranges from 0.6 to 122 per million persons per year [2] , and its prevalence ranges from 7 to 489 persons per million [2] . There are three general patterns of clinical presentation: diffuse cutaneous, limited cutaneous, and sine (Table 1) . Although efforts are underway, there are still no consistently effective antifibrotic treatments available [3] . Therefore, management of scleroderma is focused predominantly on organ-specific symptoms and mitigation of complications.
Today, pulmonary diseases account for the majority of scleroderma-attributable mortality [4•, 5] . Until the 1980s, however, scleroderma renal crisis was the most frequent cause of death [6] . The advent of angiotensinconverting enzyme (ACE) inhibitors in the late 1970s dramatically reduced scleroderma renal crisis and, as a result, mortality [7] . Subsequently, pulmonary involvem e n t h a s e m e r g e d a s t h e d o m i n a n t c a u s e o f scleroderma-attributable mortality [6] . The lack of effective antifibrotic therapies has led some physicians to consider lung transplantation for patients with end-stage scleroderma-related lung disease. This paper will review scleroderma-related lung disease, why lung transplantation for this disease is controversial, and the existing evidence evaluating key clinical outcomes such as allograft and patient survival after lung transplantation.
both. Today, scleroderma-related lung disease accounts for 45-61 % of scleroderma-related deaths [4•, 5, 6, 8] .
Nearly 40 % of patients with scleroderma have clinically significant interstitial lung disease (ILD), which most commonly manifests as nonspecific interstitial pneumonia [9] [10] [11] . Patients with diffuse cutaneous disease are more likely to have clinically significant ILD than those with limited disease [12] . Although immunosuppressive agents may slow disease progression for some, response to therapy is unpredictable. Firstline agents include mycophenolate mofetil [13] and cyclophosphamide; other options include azathioprine and rituximab. Close monitoring for response to therapy and discontinuation of treatment if no response is identified are important for patient safety.
Pulmonary arterial hypertension (PAH) is also common in scleroderma. In a retrospective study of 619 patients with scleroderma, isolated PAH was identified in 19 %, and an additional 18 % had PAH and suspected ILD overlap (based on a restrictive pattern on pulmonary function testing) [10] . PAH is a poor prognostic indicator. Indeed, in patients with scleroderma-related PAH, three-year transplant-free survival ranges between 46 % and 52 %, while those without PAH have a five-year transplant-free survival of 80 %. [14] [15] [16] . PAH-directed therapies, including ambrisentan and intravenous epoprostenol, have a less significant impact on mortality and six-minute walking distance for individuals with idiopathic PAH [17-21, 22•, 23] .
Combined ILD and PAH carries a particularly poor prognosis. In one cohort study, three-year survival was 39 %, compared to 64 % in patients with isolated PAH (p<0.01) [24] .
Lung transplantation for scleroderma-related lung disease is controversial
Although lung transplantation is a well-accepted therapeutic intervention for other types of ILD and pulmonary hypertension, the extrapulmonary involvement of scleroderma, including esophageal dysmotility, risk of scleroderma renal crisis, and malnutrition, are considered potential threats to patient and allograft survival after transplantation.
Esophageal dysmotility and acid reflux Scleroderma-related fibrosis affects the proximal gastrointestinal tract in approximately 90 % of patients [25] . The clinical impact of this fibrosis includes esophageal dysmotility, gastroesophageal reflux disease (GERD), and delayed gastric emptying. All of these factors increase the risk of macroand micro-aspiration [26] [27] [28] . Macro-aspiration, with resultant pneumonitis or pneumonia, may pose immediate threats to allograft and patient survival. Micro-aspiration is an established risk factor for the development of bronchiolitis obliterans syndrome (BOS), the most common form of chronic allograft rejection [29] [30] [31] [32] [33] . One potential mechanism by which aspiration may cause BOS is through the activation of the innate immune system [34] . In addition, esophageal dysmotility can complicate certain anti-reflux interventions such as Nissen fundoplication. Indeed, paradoxically, while fundoplication reduces retrograde refluxate, it may impede antegrade emptying of the esophagus, thereby increasing the risk of aspiration [35] . Scleroderma renal crisis Scleroderma renal crisis is defined as an abrupt onset of renal failure, often accompanied by mild to severe hypertension. It occurs in 5-15 % of patients, and may lead to permanent dialysis or death [36, 37] . Despite the use of ACE inhibitors, up to 39 % of patients with scleroderma renal crisis require permanent dialysis or die as a result of the episode [38] . And although the widespread use of ACE inhibitors has reduced the incidence of this syndrome, it presents theoretical challenges in the perioperative period after lung transplantation.
For instance, studies have demonstrated an association between increasing daily doses of corticosteroids (≥15 mg of prednisone per day) and incidence of scleroderma renal crisis [37, [39] [40] [41] . During allograft implantation, high doses of corticosteroid are a component of most induction regimens, and are also frequently used as first-line therapy for acute cellular rejection. Furthermore, calcineurin inhibitors, which are an element of immunosuppressive maintenance regimens in many programs, may cause irreversible glomerular efferent arteriolar vasospasm as well as irreversible glomerular fibrosis [42] [43] [44] . Thus, pre-existing scleroderma renal involvement or scleroderma renal crisis may require adjustments to or even preclude the use of calcineurin-inhibitor dosing, which could threaten long-term allograft survival.
Additional concerns
In addition to esophageal involvement, gastric and small bowel fibrosis may result in inconsistent absorption, leading to concerns of potential malabsorption of oral medication and malnutrition in these patients. Finally, fibrosis of the chest wall may impair wound healing after transplant surgery.
Lung transplantation for scleroderma-related lung disease: the existing evidence
Despite the concerns discussed above, several lung transplant centers do offer transplantation to patients with scleroderma. In all, nine studies reporting outcomes after lung transplantation for patients with scleroderma-related lung diseases have been published. [45-51, 52•, 53] . Combined, these retrospective cohort studies include 226 subjects and provide a reasonable base of evidence from which to evaluate key measures of transplant efficacy. These were predominantly single-center studies, with sample sizes ranging from 9 to 67 subjects (Table 2) , and all but one compared subjects with scleroderma to non-scleroderma cohorts. Survival, freedom from BOS, and acute rejection were the most frequently evaluated outcomes.
Survival after lung transplantation
While all nine studies reported survival estimates after lung transplantation, the specific time points evaluated varied among them (Table 2) . Overall, one-year survival estimates ranged from 68 % to 93 %, three-year survival from 67 % to 83 %, and five-year survival from 46 % to 76 %. The reasons for these wide ranges are not known, but may include patient selection, center-specific approach to management after lung transplantation, and chance differences due to small sample sizes. Importantly, however, all nine studies found that survival after lung transplantation for scleroderma-related lung disease was similar to that of their non-scleroderma comparison cohorts.
Few of the studies characterized esophageal dysfunction before lung transplantation, although some reported that patients with GERD or proximal gastrointestinal pathology were routinely declined for lung transplantation [48-50, 52•] . An exception is the study by Sottile et al., which evaluated survival and freedom from BOS in subjects with sclerodermarelated lung disease, some of whom had well-characterized esophageal dysfunction. At the authors' center (UC San Francisco), severe esophageal dysmotility, as measured by high-resolution manometry and pH testing, is not a contraindication to lung transplantation. Scleroderma patients are accepted for transplantation if they demonstrate no clinical evidence of aspiration and their symptoms of GERD are controlled by medication.
In the Sottile study, 23 subjects with scleroderma-related lung disease were age-and gender-matched in a 1:2 fashion to subjects with non-connective tissue disease-related ILD (nCTD-ILD). Of the 23 subjects, 12 underwent both preoperative high-resolution manometry and pH testing. Normal motility, "mild nonspecific dysmotility," and aperistalsis were each found in three subjects "severe nonspecific dysmotility" was found in two subjects, and nutcracker esophagus was observed in one. The subjects with scleroderma had one-and three-year survival estimates of 83 %, which was similar to the nCTD-ILD group. In a subgroup analysis of the 12 subjects with esophageal evaluation prior to transplant, esophageal dysmotility did not affect survival (one-and three-year survival rates of 86 % and 86 % vs. 96 % and 83 % for nCTD-ILD; p=0.99). While the authors could not identify a specific reason for the excellent medium-term survival outcomes, a proactive multidisciplinary educational program focused on aspiration prevention before and after transplantation may have been a contributing factor. Patients must adhere to strict lifestyle modifications. They must finish eating and drinking a minimum of three hours prior to lying down for the evening, must sleep on a MediWedge, and must take proton pump inhibitors. Further, in the perioperative period, speech and swallow therapists familiar with scleroderma evaluate swallowing and risk for aspiration and teach swallow-specific strengthening exercises. While feeding is always jejunal, the use of percutaneous feeding tubes varies. At UC San Francisco, percutaneous feeding tubes are used only when the approaches described above fail to mitigate aspiration. Other approaches include the routine insertion of percutaneous feeding post-transplantation for a minimum of six months. If aspiration symptoms persist beyond these measures, surgical interventions, including 270°N issen fundoplication, or Roux-en-Y anastomosis for severe dysmotility, are considered on a case-by-case basis.
In sum, the available evidence for nearly 230 patients with scleroderma-related lung disease suggests that survival after lung transplantation is equivalent to other commonly accepted disease indications.
Freedom from bronchiolitis obliterans syndrome
Freedom from BOS was reported on in four studies comprising 152 subjects [45, 47, 49, 52 •], which observed one-year freedom from BOS ranging from 70 % to 100 %, two years ranging from 63 % to 92 %, and three years, from 52 % to 75 %. Three of the studies found that freedom from BOS was equivalent between subjects with scleroderma and non-scleroderma groups [47, 49, 52 •]. The fourth study reported a trend toward increased freedom from BOS in the scleroderma group (95 % vs. 92 % at one year, 78 % vs. 61 % at five years) but did not perform tests of statistical significance. Sottile et al. reported the highest freedom from BOS, with one-, three-, and five-year estimates of 100 %, 79 %, and 79 %, respectively, despite providing lung transplantation to subjects with severe esophageal dysmotility. Interestingly, the lowest rates were reported by Saggar et al., with one-, two-, and three-year estimates of 70 %, 63 %, and 52 % respectively. The clinical approach to evaluating and managing proximal gastrointestinal pathology before and after lung transplantation is similar at the centers represented in the Sottile and Saggar studies, so an explanation for the disparity in estimates requires further investigation.
Although the findings are encouraging, no study evaluated the mechanisms underpinning equivalent survival and freedom from BOS after transplantation in subjects with scleroderma compared to non-scleroderma cohorts, and therefore any explanation for these observations is speculative. It is possible that heightened awareness of the risk of aspiration results in rigorous pre-and postoperative counseling, lifestyle modification, the use of pro-motility agents, and other interventions aimed at reducing aspiration risk, and this multipronged approach may mitigate any potential increased risk of aspiration in patients with scleroderma.
Another theory is that gastroesophageal reflux and risk of aspiration is common after lung transplantation even in patients without scleroderma. Indeed, one study found that 57 % of lung transplant candidates had elevated acid exposure times, and 36 % have esophageal hypo-or dysmotility measured by high-resolution manometry [54•] . Another study of lung transplant candidates identified that nearly 80 % had esophageal dysmotility to some degree and nearly 40 % had gastroesophageal reflux [55] . Vagal injury and medications after transplantation may further exacerbate these problems. Thus, while aspiration may be a risk to patient and allograft survival after lung transplantation, the risk very well may not be limited to patients with scleroderma.
For patients without scleroderma, small studies have demonstrated that Nissen and Dor fundoplication improve allograft function and reduce episodes of pneumonia, acute rejection, and BOS [33, 56] . While these procedures may be more difficult when scleroderma is present, anti-reflux surgical interventions tailored to scleroderma may also be considered. For example, Roux-en-Y gastric bypass has been found to improve gastroesophageal reflux disease quality-of-life scores, with fewer complications than other commonly performed anti-reflux surgeries [57] . Our center also uses partial (i.e., 270°) Nissen fundoplication or percutaneous gastrojejunostomy tube placement with jejunal feeds for patients with scleroderma-related gastroesophageal reflux and aspiration that is refractory to medical management.
Acute cellular rejection
Six of the nine studies reported acute rejection outcomes, although allograft surveillance protocols, reporting of rejection results, and methods of comparison varied substantially [45, 47-49, 51, 52•] . Four studies reported a similar incidence of acute rejection between subjects with and without scleroderma [45, 47, 48, 51] . Saggar et al., however, reported higher one-year cumulative incidence of ISHLT grade≥A2 acute rejection in patients with scleroderma compared to those with IPF (62 % versus 22 %; p=0.007) [49, 58] . Contrarily, Sottile et al. reported a lower rate of grade≥A2 rejection in patients with scleroderma compared to those with non-connective tissue disease-related ILD (1.4 versus 2.4 episodes per patient-year; p=0.05) [52•] . Although there is substantial heterogeneity among the studies, the preponderance of the data suggests that scleroderma is not associated with increased risk of acute rejection following lung transplantation.
Single vs. bilateral transplantation
Both single and bilateral lung transplantation for scleroderma are commonly performed. Of the nine studies reviewed, eight provided information on transplant type. In five studies, single lung transplantation was more common (n=103), while bilateral lung transplantation was more common in three (n=99). Only Massad et al., however, compared survival by transplant type. In that study of 47 subjects, one-year survival was 62 % for single lung and 75 % for bilateral lung transplant recipients (p=0.95). In general, little information is provided in the published literature on the clinical decisions driving the choice between single and bilateral lung transplantation.
Other
Renal complications of transplantation were mentioned in only a few studies. Crespo et al. cited one-year freedom from dialysis of 87 % in scleroderma and 98 % in non-scleroderma groups [45] . Since this information was presented only in abstract form and lacked statistical significance testing as well as other clinical details, limited conclusions can be drawn from the data. Furthermore, Rosas et al. found that mean serum creatinine at follow-up was similar between scleroderma (1.55 at a mean of 18±7 months after transplantation) and IPF/PAH comparison cohorts (1.15 at 21±4 months after transplantation) (p=0.15). Death from scleroderma renal crisis appears to be rare; only one death has been reported, at 481 days after transplantation [49] . No studies evaluated the effect of malnutrition or malabsorption on lung transplant outcomes.
Conclusions
Scleroderma is a systemic disease that may cause lifethreatening pulmonary fibrosis, pulmonary arterial hypertension, or both. The involvement of the proximal gastrointestinal system, with resultant esophageal dysmotility and risk of aspiration, has tempered enthusiasm at many centers for considering lung transplantation in this population. The existing evidence, however, demonstrates that patients undergoing lung transplantation for scleroderma-related lung diseases achieve patient and allograft survival equivalent to comparable patients without scleroderma.
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